Immunomedics (IMMU) PT Raised to $44 at BofA Securities, Sees Trodelvy Becoming 'Standard of Care'
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad raised the price target on Immunomedics (NASDAQ: IMMU) to $44.00 (from $37.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
